GlassScriptPhysician profile
Joia Adams
NPI 1023557691
$576.72
in general payments reported to CMS, 2019-2025
15 companies · $178 in 2025
The $178 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $12.66 · 2021: $73.97 · 2022: $80.13 · 2023: $112 · 2024: $121 · 2025: $178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $410.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $409.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $108.67 | 2021-2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Stryker Corporation | $98.68 | 2025 | Flowtriever, Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Abbvie INC. | $98.22 | 2022-2025 | Teflaro |
| Novartis Pharmaceuticals Corporation | $62.08 | 2022-2024 | |
| Abiomed | $45.31 | 2025 | |
| Shionogi INC | $22.06 | 2022 | |
| Recor Medical INC | $20.81 | 2024 | Paradise Renal Denervation System |
| Atricure, INC. | $18.77 | 2023 | |
| Boston Scientific Corporation | $17.75 | 2024 | Watchman Flx |
| Amarin Pharma, INC. | $15.27 | 2021 | |
| Pfizer INC. | $15.20 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $14.72 | 2021 | |
| Janssen Pharmaceuticals, INC | $14.11 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $12.66 | 2020 | |
| Alexion Pharmaceuticals, INC. | $12.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joia Adams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.